

# NeuroLicensing 2018-19



## NeuroLicensing 2018-19

**ni** Research

**NeuroLicensing 2018-19** is NI Research's completely revised and updated review of current trends in CNS deal parameters, and candid assessments of the major and midsize companies involved in CNS inlicensing. Licensing agendas and performance are reviewed and appraised. NL 2018-19 constitutes a vital resource for licensing efforts on both sides of the transaction, both licensors and licensees.

108 pages

Released August 15 2018

Available for instant download online

**US\$3750**

### NL 2018-19 Index

<b>The Macro View: The Wait for Tangible Payoffs</b>
<b>CNS Company Acquisitions</b>
<b>CNS Funding: Macro Trends</b>
<b>Funding Priorities</b>
<b>CNS Partnering: Deal Parameters</b>
<b>Partnering Priorities</b>
<b>Partnering Deal Tables: By Stage, 2009-1H:2018</b>
<b>Partnering Parameters: Upfronts and Milestones 2009-1H:18</b>
<b>Partnering Parameters: Upfronts by Stage and Year</b>
<b>Partnering Parameters: Milestones by Stage and Year</b>
<b>The Milestone Mirage: 2002-18</b>
<b>Pharma Performance: Aspirations and Execution</b>
<b>Partnering: Who Stepped Up?</b>
<b>Pharma Licensings and Payments: By Company</b>
<b>Pharma Licensing by Indication</b>
<b>Pharma Productivity: Licensing Outcomes</b>
<b>Pharma Productivity: NCEs 1995-1H:18</b>
<b>Table: CNS Licensings 2009-1H:18: Chronological</b>
<b>Table: CNS Licensings 2009-1H:18: By Company</b>
<b>Pharma CNS Licensing and Pipelines</b>
<b>Table: Big/Midsize Pharma and CNS: Interest Areas</b>
<b>Big Pharma Partnering by Therapeutic Area</b>
<b>Big Pharma Partnering Rankings: The Best to the Worst</b>
<b>Company Licensing Histories and Agendas:</b>
<i>AbbVie</i>
<i>Allergan</i>
<i>Astellas</i>
<i>AstraZeneca</i>
<i>Biogen</i>
<i>Boehringer Ingelheim</i>
<i>Eisai</i>
<i>Genentech</i>
<i>Johnson and Johnson</i>
<i>Lilly</i>
<i>Lundbeck</i>
<i>Merck</i>
<i>Mitsubishi Tanabe</i>
<i>Novartis</i>
<i>Otsuka/Avanir</i>
<i>Pfizer</i>
<i>Purdue Pharma</i>
<i>Roche</i>
<i>Sanofi</i>
<i>Servier</i>
<i>Sunovion</i>
<i>Takeda</i>
<i>UCB Pharma</i>
<b>Four To Watch: Acadia, Axovant, Biohaven, Blackthorn</b>
<b>Therapeutic Areas and Selected Licensing Candidates</b>